Photo: Sabin CEO Michael W. Marine, Ambassador (Ret.), with Former President of Ghana, John Kufuor

Sabin President Peter Hotez Testifies at House Hearings on Zika, Infectious Diseases

Peter Hotez, M.D., Ph.D., president of Sabin, testified this week at two congressional hearings: the House Energy and Commerce Subcommittee on Oversight and Investigations hearing, “Examining the U.S. Public Health Response to the Zika Virus”; and the House Foreign Affairs Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations on “The Growing Threat of Cholera and Other Diseases in the Middle East.”

Kenneth Kelley and Jordan Orange Join Sabin Vaccine Institute Board of Trustees

WASHINGTON, D.C. — January 13, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Kenneth Kelley, M.B.A., and Jordan Orange, M.D., Ph.D., to its Board of Trustees. Mr. Kelley is a Harvard Senior Advanced Leadership Fellow, focusing on global health, biosecurity and the market inefficiency leading to a lack of vaccines against neglected tropical diseases (NTDs) and emerging pandemic threats. Dr. Orange is chief of Immunology, Allergy and Rheumatology, and professor and section head for Immunology, Allergy and Rheumatology in the pediatrics department at Baylor College of Medicine.

Axel Hoos, Peter Thoren Appointed Chairman, Vice Chairman of Sabin Board of Trustees

WASHINGTON, D.C. — January 5, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the Board of Trustees unanimously appointed Axel Hoos, M.D., Ph.D., to serve as chairman of the board, and Peter L. Thoren to serve as vice chairman. Both were appointed to interim positions in December 2014.

by Peter Hotez, M.D., Ph.D. Hotez is Dean of the National School of Tropical Medicine at Baylor College of Medicine where he is also the Texas Children’s Hospital Endowed Chair in Tropical Pediatrics and the University Professor of Biology at Baylor University.

This blog post was originally published on Making Malaria History. 
 
Anyone working in global health will say the same thing: the people impacted by

Results released by the U.S. Government (USG) in September reveal that since fiscal year (FY) 2009, more than $50 billion has been invested by the USG in foreign assistance for health, saving millions of lives.

The accomplishments and work of Sabin and its three major programs — Vaccine Advocacy & Education, the Sabin Product Development Partnership (Sabin PDP) and the Global Network for Neglected Tropical Diseases (Global Network) — are highlighted in our 2013 Annual Report.

Pages